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Purpose: To examine the effectiveness and safety of photoselective vaporization of the 
prostate (PVP) with the 120 W high-performance system (HPS) Greenlight laser proce-
dure in benign prostatic hyperplasia (BPH) patients taking oral anticoagulant medi-
cations.
Materials and Methods: This study was conducted on BPH patients taking oral anti-
coagulant medications form March 2009 to December 2010. Group I consisted of pa-
tients who stopped oral anticoagulant medications before surgery (n=30), and group 
II consisted of patients who continued oral anticoagulant medications before surgery 
(n=30). PVP applying the 120 W HPS Greenlight laser was done, and followed up for 
12 weeks. Follow-up variables were International Prostate Symptom Score (IPSS), 
maximum urinary flow rate (Qmax), postvoid residual urine volume (PVR), and hemo-
globin level change.
Results: At 12 weeks after surgery, we confirmed the improvement in the IPSS score 
of Group I compared with preoperative scores. The quality of life (QoL) score, Qmax 
and PVR were also improved. respectively, both of which were significantly improved. 
In Group II, similarly, the total IPSS score, the voiding symptom score, and the storage 
symptom score were improved in comparison with the preoperative scores. The QoL 
score, Qmax and the PVR were improved in comparison with the preoperative scores. 
During the 12-week follow-up period, no major postsurgical complications requiring 
transfusion, rehospitalization, etc. were observed.
Conclusions: The 120 W HPS Greenlight laser PVP procedure can be performed effec-
tively and safely in BPH patients, even those who cannot stop oral anticoagulant medi-
cations despite requiring surgery.
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INTRODUCTION
With the aging of society, the absolute number of patients 
undergoing surgery after a diagnosis of benign prostatic 
hyperplasia (BPH) is on the increase, which could be con-
sidered to be associated with the increase in the absolute 
number of BPH patients [1]. With the development of medi-
cations, the ratio of patients requiring surgical treatment 
for BPH decreased [1]. Nonetheless, surgery should be per-
formed for bladder outlet obstruction patients who are not 
responsive to medication. Transurethral resection of the 
prostate (TURP) has a high success rate, and we can antici-
pate immediate improvement of urinary symptoms.
　In addition, owing to developments in surgical techni-
ques as well improvements in the pre- and postoperative 
management of patients, the postoperative mortality rate Korean J Urol 2011;52:178-183
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has decreased to nearly 0% [2]. However, the rate of post-
operative complications after transurethral prostatec-
tomy is 20%, which is still high [3-6], and the postoperative 
morbidity rate reaches 6.9-14%. In addition, it has been re-
ported that the rate of urinary retention due to bleeding and 
clots within 1 month after surgery is 9.5-18% [7-9], the fre-
quency of transfusion is 2-7.1%, and the rate of reoperation 
due to bleeding reaches 3-5% [2]. Because of such post-
operative bleeding complications, TURP should be per-
formed very carefully, especially in patients prone to blee-
ding.
　As a result of the ongoing prolongation of life expectancy 
as well as the aging of the population, the number of pa-
tients with cardiac diseases such as atrial fibrillation, 
thrombosis, and prosthetic valves is on the rise. To prevent 
thrombus and infarction in such patients, anticoagulant 
agents are prescribed in many cases. The surgery risk is 
high when conventional TURP is performed in such pa-
tients [10]. Thus, consensus on the selection of appropriate 
surgical methods for such patients has not yet been reached 
[11].
　The 120 W high-performance system (HPS) Greenlight 
laser minimizes bleeding by photoselective vaporization by 
use of a specific wavelength of 532 nm. In particular, it has 
been reported that with photoselective vaporization with 
a high-power laser system, the vaporization period is short 
and operator’s convenience is increased [12]. Such charac-
teristics of a laser, together with the ability of conventional 
TURP to remove the prostate, could make it safe to perform 
transurethral prostatectomy in patients prone to bleeding. 
Particularly, for older patients with cardiovascular dis-
eases for whom the administration of oral anticoagulant 
medications cannot be stopped, surgery should be per-
formed very carefully because of the risk of bleeding. 
Hence, surgery applying a laser may be safer in such 
patients. In the present study, therefore, we assessed the 
effectiveness and safety of 120 W HPS Greenlight laser 
photoselective vaporization of the prostate (PVP) in pa-
tients taking oral anticoagulant medications.
MATERIALS AND METHODS
From March 2009 to December 2010, a retrospective, ran-
domized study was performed. The study was conducted on 
60 patients who visited the department of urology for lower 
urinary tract symptoms, diagnosed as BPH, and were pre-
scribed anticoagulant medications such as aspirin and clo-
pidogrel and warfarin because of previous myocardial in-
farction and arrhythmia and cerebral vascular accident. 
Operative indications were cases with persistent symp-
toms despite appropriate treatment with alpha-blockers 
alone or in combination with 5-alpha reductase inhibitors 
for a minimum of 3 months, cases who avoided medications 
because of concerns about side effects, cases with severe 
bladder outlet obstruction diagnosed by urodynamic study 
(UDS), and cases with persistent hematuria originating 
from the prostate, bladder stones, or persistent urinary 
infection. These patients were divided into two groups: one 
group consisted of patients who stopped taking oral anti-
coagulant medications before 120 W HPS Greenlight laser 
PVP (Group I, n=30). Another group consisted of patients 
with ongoing oral anticoagulant medications who also un-
derwent 120 W HPS Greenlight laser PVP (Group II, n=30). 
The follow-up period was 3 months after surgery.
　Preoperative history taking, physical examination, com-
plete blood cell count (CBC), digital rectal examination 
(DRE), transrectal ultrasonography (TRUS), prostate- 
specific antigen (PSA) test, maximum urinary flow rate 
(Qmax), postvoid residual urine volume (PVR), the Inter-
national Prostate Symptom Score (IPSS), voiding diary, 
and UDS were performed in all patients.
　Patients with prostate-specific antigen higher than 4.0 
ng/ml, low echo lesions in TRUS, or palpated nodules in 
DRE were examined by TRUS-guided biopsy to exclude 
prostate cancer. One patient was confirmed to have pros-
tate cancer, and during conservative treatment, his lower 
urinary symptoms became severe, and thus surgery was 
performed for palliative purposes. To assess the risk of 
bleeding during the operation, we checked the hemoglobin 
test at postoperative day 1. Postoperative follow-up varia-
bles were IPSS, Qmax, and PVR, and these variables were 
assessed 12 weeks after the operation.
　For statistical analysis, we used SPSS ver. 18.0 (SPSS 
Inc., Chicago, IL, USA). For the comparison of the pre-
operative and postoperative results of each group, the 
Mann Whitney U-test was done. For the comparison of pre-
operative and postoperative results within a group, the 
Kruskall Wallis test was done. p-values less than 0.05 were 
considered to be statistically significant.
RESULTS
The mean age of the patients in Group I was 67.1±5.8 years 
and that in Group II was 71.3±5.8 years. Regarding the 
IPSS assessed before surgery, the total score of Group I was 
22.4±3.6 points and that of Group II was 21.6±7.0 points. 
The voiding symptom score of Group I was 11.7±3.6 points 
and that of Group II was 10.4±2.7 points. The symptom 
score of Group I was 10.1±2.9 points and that of Group II 
was 9.4±2.4 points. The quality of life (QoL) indexes of 
Group I and Group II were 4.4±0.7 points and 4.4±1.1 
points, respectively.
　The Qmax of Group I was 8.6±4.2 ml/s and that of Group 
II was 6.9±1.3 ml/s. The PVR of Group I was 52.9±67.9 ml 
and that of Group II was 67.5±101.8 ml.
　The prostate size measured before surgery by TRUS of 
Group I was 38.9±8.9 ml and that of Group II was 34.1±5.1 
ml. The prostate-specific antigen of Group I was 3.4±3.4 
ng/ml and that of Group II was 3.5±3.0 ng/ml. The pro-
thrombin time international normalized ratio (PT INR) of 
Group I was 1.1±0.27 and that of Group II was 0.99±0.08. 
On the basis of these results, it was confirmed that the pre-
operative condition of the two groups was not significantly 
different (Table 1).Korean J Urol 2011;52:178-183
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TABLE 1. Preoperative baseline patient characteristics
　
　
Group I Group II
p-value
Mean±SD Range Mean±SD Range
Age (yr) 67.1±5.8 56-75 71.3±5.8 58-79 0.093
PSA (ng/ml) 3.4±3.4   0.7-21.0 3.5±3.0 0.4-9.7 0.312
Transrectal US (ml) 38.9±8.9 25.0-50.5 34.1±5.1 27.0-42.9 0.837
PVR (ml) 52.9±67.9     5-240   67.5±101.8   20-220 0.293
IPSS-sum 22.4±3.6 16-28 21.6±7.0 14-29 0.162
QoL score 4.4±0.7 4-6 4.4±1.1 3-6 0.317
PT INR 1.1±0.27 0.95-1.77 0.99±0.08 0.86-1.13 0.261
SD: standard deviation, PSA: prostate-specific antigen, US: ultrasonography, PVR: postvoid residual urine volume, IPSS: International
Prostate Symptom Score, QoL: quality of life, PT INR: prothrombin time international normalized ratio
TABLE 2. Intraoperative and perioperative patient characteri-
stics
　 Group I Group II p-value
Operation 
time (min)
24.9±12.4 16.9±6.1 0.628
Total applied 
energy (J)
81,445.9±24,542.2 78,582.7±31,448.9 0.390
Hb (mg/dl)   0.6±0.53   0.5±0.49 0.886
Hb: hemoglobin change
TABLE 3. Postoperative follow-up parameters (Qmax, PVR) of 
Group I and Group II
Group I Group II
Qmax PVR (ml) Qmax PVR (ml)
Preoperation   8.6±4.2 52.9±67.9 6.9±1.3 67.5±101.8
Postoperation 24.2±7.8 4.6±9.2 14.0±4.5 9.2±19.1
Perioperative 
change
15.6±5.2 48.3±52.8 7.1±3.8 58.3±112.4
p-value 0.004 0.016 0.047
PVR: postvoid residual urine volume, Qmax: maximum urinary
flow rate
FIG. 1. The change in perioperative IPSS parameters of Group I
and Group II. IPSS: International Prostate Symptom Score, 
QoL: quality of life.
　The operation times of Group I and the Group II were 
24.9±12.4 min and 16.9±6.1 min, respectively. The average 
energy consumed during surgery was 81,445.9±24,542.2 J 
in Group I and 78,582.7±31,448.9 J in Group II. Thus, the 
amount energy delivered during surgery and the operation 
time of the two groups were not significantly different. 
During surgery, no complications developed, and Foley 
catheters were removed 1 day after surgery in all patients.
　Changes in the hemoglobin value were assessed by CBC 
performed before and after surgery. No significant changes 
in hemoglobin between before and after surgery were de-
tected in the group that ceased taking anticoagulant drugs 
or in the group who continuously took anticoagulant agents 
(p＜0.05) (Table 2).
　At 12 weeks after surgery, the IPSS of each group was 
assessed compared with the preoperative values. In Group 
I, the total score was 6.2±3.2 points, the voiding symptom 
score was 2.6±3.3 points, and the storage symptom score 
was 3.6±2.0 points, which were improved in comparison 
with the scores before surgery. The QoL score was 1.8±0.8 
points, and it was also improved in comparison with the 
preoperative score. Qmax and PVR after surgery were 
24.2±7.8 ml/s and 4.6±9.2 ml, respectively, which were im-
proved in comparison with the preoperative scores (Table 
3). In Group II, similarly, the IPSS total score was 11.4±5.9 
points, the voiding symptom score was 4.8±4.0 points, and 
the storage symptom score was 4.1±4.2 points, which were 
improved in comparison with the preoperative scores. The 
QoL score was 2.1±1.4 points, and it was confirmed to be 
improved. Qmax was 14.0±4.5 ml/s and PVR was 9.2±19.1 
ml, which were also improved in comparison with the pre-
operative score (Table 3). 
　The changes in perioperative IPSS parameters of Group 
I and Group II were not significantly different (Fig. 1). 
During 12 weeks of follow-up, none of patients in the two 
groups developed hematuria, impotence, urethral stric-
ture, infection, or other complications.
DISCUSSION
With the development of medicines, human life expectancy Korean J Urol 2011;52:178-183
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is prolonged; consequently, the elderly population group is 
on the increase. Generally, with aging, the possibility of de-
veloping cerebral and cardiovascular diseases is increased, 
and the number of patients taking anticoagulant medi-
cations to prevent these diseases is also on the rise. The in-
crease in the number of patients developing geriatric dis-
eases can be confirmed by the increase in the number of 
BPH patients in the urological field [1].
　In such aging patients, regardless of forms or purposes, 
the interruption of anticoagulants may increase the risk of 
thrombus, and thus attention should be paid to this point 
[11]. In TURP for general geriatric patients, the incidence 
of deep vein thrombosis reaches 6.8-10% [10]; thus, more 
comprehensive attention is required.
　To reduce such risk in patients taking anticoagulants, we 
usually stop oral administration of anticoagulant agents 
for 3 to 4 days before surgery, and heparin is injected 
intravenously. Because the onset and reactive time of the 
heparin family is short, we can easily control it [13,14]. 
Despite such efforts, we can find reports of transfusion or 
rehospitalization after conventional TURP because of 
bleeding tendency. Chakravarti and MacDermott reported 
that for 11 patients under oral anticoagulant therapy, un-
fractionated heparin was injected intravenously from 2 
days before surgery. After conventional TURP, one patient 
required transfusion and persistent hematuria occurred in 
27% patients, although mild, and some patients required 
rehospitalization [13]. Dotan et al reported that in 20 pa-
tients receiving warfarin medication, LMW-heparin was 
administered before surgery. After conventional TURP, 
20% of patients required transfusion, and in 10% of cases, 
a Foley catheter was indwelled again because of persistent 
hematuria or bleeding [15].
　Preoperative anticoagulant medication reduces the lev-
el of risk for thrombus or infarction. On the other hand, it 
was observed that the bleeding tendency during and after 
the operation is maintained. In addition, in the elderly 
group, complications due to deep vein thrombosis may de-
velop in approximately 6.8% to 10% of surgical patients, 
and thus the decision to use anticoagulants for prostate 
surgery is hard [10,16].
　In this condition, 120 W HPS Greenlight laser PVP is 
drawing attention recently as a minimally invasive sur-
gery that could replace conventional TURP [17,18]. In par-
ticular, we suggested it as a new option for patients receiv-
ing anticoagulant agents who require TURP.
　In the urology field, after KTP laser TURP, the effective-
ness and techniques of laser surgery have rapidly improved 
[19]. According to recent studies, laser PVP is one of the 
minimally invasive surgeries that have replaced conven-
tional TURP [20].
　PVP has the ability of conventional TURP to remove 
prostate tissues and the safety of a laser [21,22]. In short- 
term studies, the effectiveness and side effects were not 
greatly different from those of transurethral prosta-
tectomy. There is no difference between PVP and conven-
tional TURP in symptom improvement or reoperation 
risks. In particular, the risk of reoperation because of bleed-
ing tendency is lower [23-28]. In addition, we can find many 
reports with good results, showing application in a large 
prostate that requires open surgery [27,29] or in a poor 
prognostic patient with a preoperative history of frequent 
retention [30]. 
　As shown by our results, for patients taking oral anti-
coagulant therapy, PVP is a safe and effective procedure. 
This is because thrombus formation could be prevented by 
the continuous administration of anticoagulants, and 
bleeding and other complications could be prevented by 
PVP with a laser.
　The purpose of surgery for the prostate is to improve uri-
nary symptoms and to prevent complications caused by 
acute and chronic urinary retention. In our study con-
ducted on the initial 60 cases of a high-risk group of pa-
tients, for 30 patients, the operation was performed after 
interrupting anticoagulant therapy, and for the remaining 
30 patients, surgery was performed while maintaining an-
ticoagulant therapy. Between these the two groups, there 
were no significant differences in preoperative variables 
such as age, IPSS, PSA, or the size of the prostate. Also, 
there were no significant differences in mean operation 
time or intraoperative energy consumption.
　After surgery, no acute complications such as bleeding 
or urinary retention were observed in either group. In re-
gard to postoperative urinary symptoms, the Qmax of the 
two groups was improved from 8.6 ml/s to 24.2 ml/s and 
from 6.9 ml/s to 14.1 ml/s, respectively. The PVR of the two 
groups was significantly improved from 52.9 ml to 4.6 ml 
and from 67.5 ml to 9.2 ml, respectively. In both groups, the 
objective index of all urinary symptoms was significantly 
improved in comparison with before the operation.
　In addition, the preoperative and postoperative IPSS of 
the two groups was 22.4 points and 6.2 points, and 21.6 
points and 11.4 points, respectively. We confirmed that 
there was significant statistical improvement. We also con-
firmed that the average IPSS voiding symptom score sig-
nificantly improved from 11.7 points to 2.6 points and from 
10.4 points to 4.8 points. The average IPSS storage symp-
tom score of the two groups significantly improved from 
10.1 points to 3.6 points and from 9.4 points to 4.1 points, 
respectively. The QoL score of group I improved from 4.4 
points to 1.8 points and that of group II improved from 4.4 
points to 2.1 points. The improvements in this subjective 
index were also shown to be statistically significant. The 
postoperative change in hemoglobin in group I and group 
II was 0.6 mg/dl and 0.5 mg/dl, respectively. There was no 
significant intergroup (group I/II) difference and no sig-
nificant intragroup (pre/post operation) difference either. 
These results support the conclusion that the 120 W HPS 
Greenlight laser PVP procedure is safe, even in high-risk 
patients taking anticoagulant therapy.
　In the comparison of the two groups, it appeared that in 
the group maintained on anticoagulant therapy, operation 
time was shorter and the average energy consumed during 
surgery was less than in the group in which anticoagulant Korean J Urol 2011;52:178-183
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therapy was interrupted, which could be thought to be due 
to the surgeon’s concerns for bleeding. Nonetheless, these 
differences were not statistically significant. 
　Besides the improvement of postoperative urinary symp-
toms, the complication rate is also an important variable. 
In our study, the long-term, follow-up observation is cur-
rently ongoing, but to date, none of the patients have pre-
sented with urethral stricture or bladder neck stricture. 
Long-term follow-up observation for stricture is required 
in the future.
　The 120 W HPS Greenlight PVP method may minimize 
bleeding and the consequent risk for transfusion, espe-
cially for patients with lower urinary tract symptoms and 
bleeding tendency. This report is considered to be valuable 
because it is the first study in Korea showing that 120 W 
HPS Greenlight laser PVP can be performed safely and ef-
fectively in BPH patients who require maintenance of oral 
anticoagulants. Long-term follow-up observation on a 
larger number of patients is required and is planned.
CONCLUSIONS
For BPH patients taking anticoagulant medications for the 
treatment or prevention of cardiac or cerebral diseases who 
require surgical BPH treatments, 120 W HPS Greenlight 
laser PVP is considered to be an effective and safe surgical 
method. On the basis of our experiences, we suggest that 
120 W HPS Greenlight PVP be considered the standard 
procedure for such patients with a high risk of bleeding, 
while maintaining anticoagulant therapy.
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